DK1325011T3 - Fremgangsmåder og forbindelser til behandling af proliferative sygdomme - Google Patents

Fremgangsmåder og forbindelser til behandling af proliferative sygdomme

Info

Publication number
DK1325011T3
DK1325011T3 DK01972948T DK01972948T DK1325011T3 DK 1325011 T3 DK1325011 T3 DK 1325011T3 DK 01972948 T DK01972948 T DK 01972948T DK 01972948 T DK01972948 T DK 01972948T DK 1325011 T3 DK1325011 T3 DK 1325011T3
Authority
DK
Denmark
Prior art keywords
treatment
compounds
methods
proliferative diseases
formula
Prior art date
Application number
DK01972948T
Other languages
English (en)
Inventor
Kelly Wayne Furness
Sushant Malhotra
David Keyes Clawson
Thomas Albert Engler
Stephen Lyle Briggs
Harold Burns Brooks
Concepcion Sanchez-Martinez
Faming Zhang
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1325011T3 publication Critical patent/DK1325011T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
DK01972948T 2000-09-29 2001-09-24 Fremgangsmåder og forbindelser til behandling af proliferative sygdomme DK1325011T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23661600P 2000-09-29 2000-09-29
PCT/US2001/027728 WO2002028861A2 (en) 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
DK1325011T3 true DK1325011T3 (da) 2004-08-16

Family

ID=22890242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01972948T DK1325011T3 (da) 2000-09-29 2001-09-24 Fremgangsmåder og forbindelser til behandling af proliferative sygdomme

Country Status (10)

Country Link
US (1) US7109229B2 (da)
EP (1) EP1325011B1 (da)
AT (1) ATE266031T1 (da)
AU (1) AU2001292579A1 (da)
DE (1) DE60103171T2 (da)
DK (1) DK1325011T3 (da)
ES (1) ES2220811T3 (da)
PT (1) PT1325011E (da)
TR (1) TR200401316T4 (da)
WO (1) WO2002028861A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
CN101547923A (zh) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
MX2009006454A (es) 2006-12-22 2009-06-26 Hoffmann La Roche Derivados de espiro-piperidina.
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CA2738909A1 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
EP2367829B1 (en) 2008-11-19 2013-01-02 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
ES2530015T3 (es) * 2010-05-18 2015-02-25 Cephalon, Inc. Método para purificar un derivado de pirrolocarbazol fusionado
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
PT2968290T (pt) 2013-03-15 2019-11-27 G1 Therapeutics Inc Protecção transitória de células normais durante a quimioterapia
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
EP1325011A2 (en) 2003-07-09
WO2002028861A8 (en) 2003-11-20
DE60103171T2 (de) 2004-11-11
US20040048915A1 (en) 2004-03-11
ES2220811T3 (es) 2004-12-16
EP1325011B1 (en) 2004-05-06
PT1325011E (pt) 2004-09-30
TR200401316T4 (tr) 2004-07-21
DE60103171D1 (de) 2004-06-09
ATE266031T1 (de) 2004-05-15
WO2002028861A3 (en) 2002-08-01
US7109229B2 (en) 2006-09-19
AU2001292579A1 (en) 2002-04-15
WO2002028861A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
NO20045043L (no) Pyrimidinonforbindelser, sammensetninger og fremgangsmater
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
NO20070782L (no) Tetrapeptidanaloger.
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
DK1377589T3 (da) Oxazolyl-pyrazolderivater som kinaseinhibitorer
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
TW200508233A (en) Chk-1 inhibitors
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
DE60106947D1 (de) Oxindolderivate
EA200700692A1 (ru) Пиридиновые производные индолин-2-она, их получение и их прменение в терапии